Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Verrill

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|November 6, 2025
Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challengesMark Verrill, Michael Patrick Lux, Joseph Gligorov, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2014
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracilDavid Jamieson, Jo Lee, Nicola Cresti, et al.
BMC Cancer|July 1, 2010
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trialsLesley A Smith, Victoria R Cornelius, Christopher J Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesRuth Plummer, Penella Woll, David Fyfe, et al.
Health and Quality of Life Outcomes|November 3, 2020
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stageMark Verrill, Andrew M Wardley, Jenny Retzler, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2011
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinibJiri Horak, Jeff White, Adrian L Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesotheliomaAndy Hughes, Paula Calvert, Ashraf Azzabi, et al.
The Oncologist|July 19, 2018
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III StudyKyung Hae Jung, Beyhan Ataseven, Mark Verrill, et al.
BMJ Open|May 14, 2026
Age, patient experience and satisfaction with breast cancer care: a cohort study using linked national cancer patient experience survey and cancer registry dataSarah Blacker, Diana R Withrow, Jemma M Boyle, et al.
British Journal of Cancer|July 19, 2023
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient ProgramCarlo Palmieri, Alison Musson, Catherine Harper-Wynne, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|November 6, 2025
Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challengesMark Verrill, Michael Patrick Lux, Joseph Gligorov, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2014
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracilDavid Jamieson, Jo Lee, Nicola Cresti, et al.
BMC Cancer|July 1, 2010
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trialsLesley A Smith, Victoria R Cornelius, Christopher J Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesRuth Plummer, Penella Woll, David Fyfe, et al.
Health and Quality of Life Outcomes|November 3, 2020
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stageMark Verrill, Andrew M Wardley, Jenny Retzler, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2011
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinibJiri Horak, Jeff White, Adrian L Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesotheliomaAndy Hughes, Paula Calvert, Ashraf Azzabi, et al.
The Oncologist|July 19, 2018
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III StudyKyung Hae Jung, Beyhan Ataseven, Mark Verrill, et al.
BMJ Open|May 14, 2026
Age, patient experience and satisfaction with breast cancer care: a cohort study using linked national cancer patient experience survey and cancer registry dataSarah Blacker, Diana R Withrow, Jemma M Boyle, et al.
British Journal of Cancer|July 19, 2023
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient ProgramCarlo Palmieri, Alison Musson, Catherine Harper-Wynne, et al.
Pageof 4